{Reference Type}: Journal Article
{Title}: The Answer ALS return of results study: Answering the duty to disclose.
{Author}: Roggenbuck J;Kaschalk M;Eustace R;Vicini L;Gokun Y;Harms MB;Kolb SJ;
{Journal}: Amyotroph Lateral Scler Frontotemporal Degener
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 2
{Factor}: 3.528
{DOI}: 10.1080/21678421.2024.2385004
{Abstract}: Objective: The Return of Answer ALS Results (RoAR) Study was designed to provide a mechanism for participants in Answer ALS, a large, prospectively designed natural history and biorepository study to receive select clinical genetic testing results and study participants' experience with the results disclosure. Methods: Participants consented to receive results of five ALS genes (C9orf72, SOD1, FUS, TARDP, TBK1) and/or 59 medically actionable genes as designated by the American College of Medical Genetics. Patient-reported genetic testing outcomes were measured via a post-disclosure survey. Results: Of 645 eligible Answer ALS enrollees, 143 (22%) enrolled and completed participation in RoAR. Pathogenic variants were identified in 22/143 (15.4%) participants, including 13/143 (9.0%) in ALS genes and 9/143 (6.3%) in ACMG genes. Participant-reported measures of result utility indicated the research result disclosure was as or more successful than published patient-reported outcomes of result disclosure the clinical setting. Conclusions: This study serves as a model of a "disclosure study" to share results from genomic research with participants who were not initially offered the option to receive results, and our findings can inform the design of future, large scale genomic projects to empower research participants to access their genetic information.